Literature DB >> 26550224

The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.

Shu-Jin Wang1, Zhong-Sen Qu2, Qing-De Zhang3, Liang Li4, Feng Wang2, Bin Zhang2, Bang-Li Wu1, Yu-Wu Zhao2.   

Abstract

To investigate the effect of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction. 112 cases of uremia complicated with cerebral infarction were randomly divided into the peritoneal dialysate with urokinase treatment group (66 cases) and the conventional treatment group (46 cases). At the same time, 50 cases of healthy people who were more than 45 years old were enrolled in the control group. The basic treatment in both treatment groups was the same. In urokinase therapy group based on the conventional treatment, urokinase was added into peritoneal dialysis fluid, and changes of serum MMP-9, MMP-2 and vWF were observed by drawing blood at different time points within 8 weeks. The changes of serum MMP-2, MMP-9 and vWF were detected by enzyme-linked immunosorbent assay. At the time of the onset of uremia complicated with cerebral infarction patients the serum MMP-9, MMP-2, vWF were significantly higher (P<0.05, P<0.05, P<0.01). Conventional antiplatelet therapy in brain protection only reduce MMP-9 to the normal range (P>0.05) within 8 weeks. But the MMP-2 and vWF cannot be reduced to the normal range (P<0.01, P<0.01). Low doses of urokinase can reduce MMP-9 (7 d) and MMP-2 (14 d) to the normal range (P>0.05, P>0.05) at the early stage and decrease the vWF to a normal range within 8 weeks (P>0.05). At the time of the onset of uremia complicated with cerebral infarction patients the serum MMP-9, MMP-2 and vWF increased significantly. Low doses of urokinase dialysis can reduce serum MMP-9, MMP-2, and vWF in acute uremia complicated with cerebral infarction without recurrence of cerebral infarction and cerebral hemorrhagic transformation, indicating that low dose of urokinase peritoneal dialysis may have a certain effect on the early treatment of this disease.

Entities:  

Keywords:  Uremia; infarction; matrix metalloproteinases; urokinase; von Willebrand factor

Year:  2015        PMID: 26550224      PMCID: PMC4612909     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  39 in total

1.  Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis.

Authors:  Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Journal:  Clin Biochem       Date:  2011-04-16       Impact factor: 3.281

Review 2.  The urokinase system in the pathogenesis of atherosclerosis.

Authors:  Bianca Fuhrman
Journal:  Atherosclerosis       Date:  2011-11-16       Impact factor: 5.162

3.  Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients.

Authors:  Michelle A H Sonneveld; Anouk C van Dijk; Evita G van den Herik; Janine E van Loon; Lonneke M L de Lau; Aad van der Lugt; Peter J Koudstaal; Moniek P M de Maat; Frank W G Leebeek
Journal:  Atherosclerosis       Date:  2013-08-02       Impact factor: 5.162

4.  Endothelial dysfunction in uremic patients on continuous ambulatory peritoneal dialysis (CAPD).

Authors:  Senija Rašić; Almira Hadžović-Džuvo; Damir Rebić; Amina Valjevac; Snežana Unčanin
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

5.  A pilot study of urokinase therapy in cerebral infarction.

Authors:  A P Fletcher; N Alkjaersig; M Lewis; V Tulevski; A Davies; J E Brooks; W B Hardin; W M Landau; M E Raichle
Journal:  Stroke       Date:  1976 Mar-Apr       Impact factor: 7.914

6.  Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients.

Authors:  Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

7.  Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.

Authors:  Makio Nagano; Kei Fukami; Sho-ichi Yamagishi; Seiji Ueda; Yusuke Kaida; Takafumi Matsumoto; Junko Yoshimura; Takuma Hazama; Yoshimi Takamiya; Takuo Kusumoto; Shojiro Gohara; Hideharu Tanaka; Hisashi Adachi; Seiya Okuda
Journal:  Am J Nephrol       Date:  2008-08-14       Impact factor: 3.754

8.  Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.

Authors:  Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Journal:  Atherosclerosis       Date:  2006-02-28       Impact factor: 5.162

9.  Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.

Authors:  B Savage; F Almus-Jacobs; Z M Ruggeri
Journal:  Cell       Date:  1998-09-04       Impact factor: 41.582

10.  Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease.

Authors:  Ada W Y Chung; H H Clarice Yang; Jong Moo Kim; Mhairi K Sigrist; Elliott Chum; William A Gourlay; Adeera Levin
Journal:  Circulation       Date:  2009-08-17       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.